With the Pharmafocus team having avoided hurricane Florence and finally arriving back in the UK just last night, after stopping by the FlyPharma 2018 Conference in Miami, FLA it’s time to look over this week’s top ten most popular news stories.
Topping the list is the news that FDA recruitment official Melanie Keller has said that Trump is making it difficult to attract top talent; a claim which has been disputed by others inside the organisation.
Meanwhile UK Health Secretary Matt Hancock took a page out of President Trump’s book in condemning ‘rip off’ pharma companies who he accused of ‘ripping off taxpayers’. Protests also erupted in Manchester over NICE’s decision not to approve the $750,000 drug Spinraza, while NICE also rejected Bristol Myers Squibb’s Opdivo.
Nevertheless while our feature on drug safety after Brexit reached the top three, Novo Nordisk announced that they were stockpiling 16 weeks’ worth of insulin in preparation for a hard, no-deal exit from the EU.
To find out more, check out this week’s Top 10 most popular articles on Pharmafile.com now!
Novartis has revealed data from a range of multinational, real-world studies which reinforced the efficacy of its interleukin-17A inhibitor Cosentyx (secukinumab) in the treatment of moderate-to-severe psoriasis.
Keytruda has been approved in Europe in combination with permextred and platinum-based chemotherapy in the first-line treatment of metastatic non-squamous non-small cell lung cancer in adults with no EGFR or ALK positive mutations
Alcon, the eyecare unit of Novartis, is set to move to a new home next year, after its parent company revealed that the Swiss city of Geneva had been chosen as its new headquarters.
Protesters in Manchester have called on the National Institute of Health and Care Excellence (NICE), to overturn their rejection of the Spinal Muscular Atrophy (SMA) treatment Spinraza, after the public body chose not to approve the orphan drug for use on the NHS due “to uncertainties over its long-term effectiveness and its extremely high cost.”
Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease.
The FDA is to incorporate real-world data elements to a greater degree into its regulatory decision-making framework in a bid to “answer questions that are relevant to broader patient populations or treatment settings where information may not be captured through traditional clinical trials.”
British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business should act in a more socially responsible manner, in an interview with the British newspaper, The Times.
What does Brexit mean for drug safety in Europe and the United Kingdom? Louis Goss looks into Britain’s exit from the European Union and asks what the future might hold for pharmacovigilance on both sides of the channel.
Danish multinational Novo Nordisk has announced that they are increasing their stocks of insulin products to ensure that there have 16 weeks’ worth of supplies, in preparation for a hard no deal Brexit.
Melanie Keller, Acting Associate Commissioner for Scientific and Clinical Recruitment at the US Food and Drug Administration (FDA) has said that the Trump administration restrictions on hiring those who have lived outside of the United States, has made it difficult for the agency to attract top talent.